Logo

Covistat, Biopharmaceutical Company Developing Low-Cost COVID-19 Treatment, Acquires IP From World Leader in Respiratory Disease Medicine

Share this
Covistat, Biopharmaceutical Company Developing Low-Cost COVID-19 Treatment, Acquires IP From World Leader in Respiratory Disease Medicine

M&A

Covistat, Biopharmaceutical Company Developing Low-Cost COVID-19 Treatment, Acquires IP From World Leader in Respiratory Disease Medicine

Technology, expertise from UK's Mucokinetica to accelerate repurposing of generic remedy nafamostat for COVID-19 oral, inhalation therapy SAN DIEGO,?Aug. 6, 2020?/PRNewswire/ --?A?biopharmaceutical?company?repurposing?nafamostat, a generic remedy for?pancreatitis?and acute kidney injury, is one step closer to a treatment in its fight against COVID-19.?Covistat, an?Ensysce?Biosciences?subsidiary, today announced its acquisition of Mucokinetica's?technology and intellectual property, which will accelerate efforts to develop a low-cost treatment that helps the body's ability to block the?coronavirus?and?its mutating?variations?from?infiltrating our cells. London-based Dr.?Peter Cole?and Dr.?Rod Hall, founders of?Mucokinetica?Ltd. and?world-leading experts in the development of medicines to treat respiratory diseases such as cystic fibrosis,?are joining the?Covistat?team. Nafamostat, with its anticoagulant and anti-inflammatory properties, has for 30 years been safely used intravenously to treat?pancreatitis?patients.?Nafamostat?works by affecting the body's own enzymes?not?the virus, which is capable of mutating to evade treatments.?Nafamostat?blocks TMPRSS2, the enzyme that enables SARS-CoV-2's spike proteins to gain entry into cells. Whether suffering from mild symptoms at home or acute respiratory failure in a hospital, nafamostat's therapy?is expected to reduce the viral load in patients and prevent the progression of COVID-19. Covistat?is working to?repurpose?this proven generic drug into oral, intranasal and inhaled therapies for COVID-19 patients, including those in remote and developing regions of the world. Compared to intravenous treatments, oral drugs are often significantly less costly and highly accessible to more people in the U.S. and around the world. Oral medications also often are preferred for their stability?longer?shelf lives and easier transportation with little need for temperature-controlled storage typically limited to hospital settings. Mucokinetica?is known for its decades of research, deep technical expertise and technology advancements in?inhaled and intranasal administration of?nafamostat, which safely delivers the generic drug directly into the lungs of patients suffering from respiratory diseases. "The?Mucokinetica?team has dedicated their lives to fighting devastating diseases. Together, we can formulate the safest, most accessible treatment to reduce progression of this powerful virus and help protect against COVID-19, as well as future strains and other seasonal?coronaviruses," Dr. Lynn Kirkpatrick,?Covistat?CEO, said. MEDIA CONTACT: Drive West Communications,?Covistat@DriveWest.com,?281.220.6861 ext. 701 SOURCE Covistat

Share this article on WhatsApp, LinkedIn and Twitter



Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions